-
公开(公告)号：US20230295213A1
公开(公告)日：2023-09-21
申请号：US17993937
申请日：2022-11-24
Applicant: RISEN (SUZHOU) PHARMA TECH CO., LTD.
Inventor： Jiasheng LU , Gang CHEN , Qiguo ZHANG , Xianqi KONG , Dawei CHEN , Chuanhao HUANG , Xingwu ZHU , Yuhua ZHANG
IPC: C07H19/20 , C07H19/16 , C07F9/6561
CPC classification number: C07H19/20 , C07H19/16 , C07F9/65616
Abstract: CD73 (also known as ecto-5′-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I′ and pharmaceutically acceptable esters or salts thereof.
-
公开(公告)号：US20220204541A1
公开(公告)日：2022-06-30
申请号：US17548899
申请日：2021-12-13
Inventor： Jiasheng LU , Jiamin GU , Gang CHEN , Xiaolin ZHANG , Feng ZHOU , Xianqi KONG
IPC: C07F9/6574 , C07D401/14 , C07D401/12 , C07F9/22
Abstract: There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for inhibition or modulation of the activity of cyclin dependent kinases (CDK) and/or glycogen synthase kinase-3 (GSK-3), for the treatment of disease states or conditions mediated by cyclin dependent kinases and/or glycogen synthase kinase-3, including cancers.
-
公开(公告)号：US20210139526A1
公开(公告)日：2021-05-13
申请号：US17133348
申请日：2020-12-23
Applicant: RISEN (SUZHOU) PHARMA TECH CO., LTD.
Inventor： Jiasheng LU , Jiamin GU , Gang CHEN , Feng ZHOU , Qiguo ZHANG , Xuli WANG , Xiang JI , Lin WANG , Xianqi KONG
IPC: C07H19/20 , C07H19/23 , A61K31/7076 , A61K39/395
Abstract: CD73 (also known as ecto-5′-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I and pharmaceutically acceptable esters or salts thereof.
-
公开(公告)号：US20200078388A1
公开(公告)日：2020-03-12
申请号：US16566327
申请日：2019-09-10
Applicant: RISEN (SUZHOU) PHARMA TECH CO. LTD.
Inventor： Jiasheng LU , Jiamin GU , Dongdong WU , Gang CHEN , Chengyong SUN , Xiang JI , Lin WANG , Feng ZHOU , Xiuchun ZHANG , Xianqi KONG
IPC: A61K31/7076 , A61K9/00 , A61K39/395 , C07H19/20 , C07H19/16
Abstract: CD73 (also known as ecto-5′-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I and pharmaceutically acceptable esters or salts thereof.
-
公开(公告)号：US20240158343A1
公开(公告)日：2024-05-16
申请号：US18417291
申请日：2024-01-19
Applicant: RISEN (SUZHOU) PHARMA TECH CO., LTD.
Inventor： Jiasheng LU , Jiamin GU , Xinyong LV , Guowei SONG , Dongdong WU , Daiqiang HU , Jun GU , Gang CHEN , Xiang JI , Xiuchun ZHANG , Jinchao AI , Xianqi KONG
IPC: C07C309/14 , C07B59/00 , C07C309/15 , C07C309/59 , C07D233/61
CPC classification number: C07C309/14 , C07B59/001 , C07B59/002 , C07C309/15 , C07C309/59 , C07D233/61 , C07B2200/05
Abstract: There are provided isotope-enriched compounds of Formula (I) and pharmaceutically acceptable salts or esters thereof, as well as pharmaceutical compositions thereof and methods of use thereof for prevention and treatment of amyloid-β related diseases, such as Alzheimer's disease.
R1R2X—CR2—CH2—CH2—SO3H (I)-
Patent Agency Ranking
公开(公告)号：US20210347731A1
公开(公告)日：2021-11-11
申请号：US17140450
申请日：2021-01-04
Applicant: RISEN (SUZHOU) PHARMA TECH CO., LTD.
Inventor： Jiasheng LU , Jiamin GU , Xinyong LV , Guowei SONG , Dongdong WU , Daiqiang HU , Jun GU , Gang CHEN , Xiang JI , Xiuchun ZHANG , Jinchao AI , Xianqi KONG
IPC: C07C309/14 , C07C309/15 , C07B59/00 , C07C309/59 , C07D233/61
Abstract: There are provided isotope-enriched compounds of Formula (I) and pharmaceutically acceptable salts or esters thereof, as well as pharmaceutical compositions thereof and methods of use thereof for prevention and treatment of amyloid-β related diseases, such as Alzheimer's disease. R1R2X—CR2—CH2—CH2—SO3H (I)
-
公开(公告)号：US20200339615A1
公开(公告)日：2020-10-29
申请号：US16856603
申请日：2020-04-23
Inventor： Jiasheng LU , Jiamin GU , Gang CHEN , Xiaolin ZHANG , Feng ZHOU , Xianqi KONG
IPC: C07F9/6574 , C07F9/22 , C07D401/14 , C07D401/12
Abstract: There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for inhibition or modulation of the activity of cyclin dependent kinases (CDK) and/or glycogen synthase kinase-3 (GSK-3), for the treatment of disease states or conditions mediated by cyclin dependent kinases and/or glycogen synthase kinase-3, including cancers.
-
公开(公告)号：US20240024346A1
公开(公告)日：2024-01-25
申请号：US18021709
申请日：2021-11-25
Applicant: RISEN (SUZHOU) PHARMA TECH CO., LTD. , Jiasheng LU , Gang CHEN , Qiguo ZHANG , Xianqi KONG , Dawei CHEN , Chuanhao HUANG , Xingwu ZHU , Yuhua ZHANG
Inventor： Jiasheng LU , Gang CHEN , Qiguo ZHANG , Xianqi KONG , Dawei CHEN , Chuanhao HUANG , Xingwu ZHU , Yuhua ZHANG
IPC: A61K31/7076 , C07H19/20 , A61K45/06
CPC classification number: A61K31/7076 , A61K45/06 , C07H19/20
Abstract: CD73 (also known as ecto-5′-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I′ and pharmaceutically acceptable esters or salts thereof.
-
公开(公告)号：US20210078970A1
公开(公告)日：2021-03-18
申请号：US17005852
申请日：2020-08-28
Applicant: RISEN (SUZHOU) PHARMA TECH CO., LTD.
Inventor： Jiasheng LU , Jiamin GU , Gang CHEN , Qiguo ZHANG , Chengyong SUN , Xianqi KONG
IPC: C07D401/06 , A61K9/00 , A61P35/00 , C07D231/56 , C07D405/14 , C07F9/06
Abstract: There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, useful for inhibition or modulation of the activity of tyrosine kinases and treatment of disease states or conditions mediated by tyrosine kinases, including cancers.
-
公开(公告)号：US20230295079A1
公开(公告)日：2023-09-21
申请号：US17993389
申请日：2022-11-23
Applicant: RISEN (SUZHOU) PHARMA TECH CO., LTD.
Inventor： Jiasheng LU , Jiamin GU , Xinyong LV , Guowei SONG , Dongdong WU , Daiqiang HU , Jun GU , Gang CHEN , Xiang JI , Xiuchun ZHANG , Jinchao AI , Xianqi KONG
IPC: C07C309/14 , C07C309/15 , C07B59/00 , C07C309/59 , C07D233/61
CPC classification number: C07C309/14 , C07C309/15 , C07B59/001 , C07B59/002 , C07C309/59 , C07D233/61 , C07B2200/05
Abstract: There are provided isotope-enriched compounds of Formula (I) and pharmaceutically acceptable salts or esters thereof, as well as pharmaceutical compositions thereof and methods of use thereof for prevention and treatment of amyloid-β related diseases, such as Alzheimer's disease.
R1R2X—CR2—CH2—CH2—SO3H (I)
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.017 seconds)
